Moderna, Inc. (MRNA) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $49.87: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 18%; Below-average business quality; Rich valuation.
Moderna is an mRNA medicine company with three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (RSV vaccine for adults). Total revenue was $1.9 billion in 2025, largely from COVID vaccine sales, while the pipeline of 35 programs spans infectious disease,... Read more
Sell if holding. Engine safety override at $49.87: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 18%; Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Score 4.6/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 47d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Moderna, Inc.
Latest news
- NEWS Reported Earlier, Moderna And University Of Oxford Receive UK MHRA Authorization To Begin Phase 1/2 Study Of mRNA Cancer — benzinga Jun 9, 2026 positive
- NEWS B of A Securities Maintains Underperform on Moderna, Raises Price Target to $34 — benzinga Jun 8, 2026 negative
- NEWS U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts — benzinga Jun 5, 2026 neutral
- NEWS Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls — benzinga Jun 1, 2026 positive
- NEWS Moderna And Merck Present 5-Year Data For Intismeran Autogene in Combination With KEYTRUDA In Patients With High-Risk St — benzinga Jun 1, 2026 positive
Generated 2026-06-15T12:26:44Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCOVID vaccines10-K Item 1: 'In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $49.87: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 18%; Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Prior stop was $46.42. Score 4.6/10, moderate confidence.
Take-profit target: $50.86 (+1.9% upside). Prior stop was $46.42. Stop-loss: $46.42.
Concentration risk — Product: COVID vaccines; Target reached (-21.9% upside); Quality below floor (3.1 < 4.0).
Moderna, Inc. trades at a P/E of N/A (forward -11.9). TrendMatrix value score: 3.5/10. Verdict: Sell.
30 analysts cover MRNA with a consensus score of 2.8/5. Average price target: $43.
What does Moderna, Inc. do?Moderna is an mRNA medicine company with three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA...
Moderna is an mRNA medicine company with three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (RSV vaccine for adults). Total revenue was $1.9 billion in 2025, largely from COVID vaccine sales, while the pipeline of 35 programs spans infectious disease, oncology, and rare disease.